MAZE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
-100.0%
20.0M
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
20.0M
0
0
Operating Expenses
51.5M
+7.2%
48.0M
+3.2%
46.6M
+22.3%
38.1M
+15.5%
33.0M
R&D
40.2M
+15.1%
34.9M
+2.3%
34.1M
+23.9%
27.6M
+9.4%
25.2M
SG&A
11.3M
-13.7%
13.1M
+5.6%
12.4M
+18.3%
10.5M
+34.9%
7.8M
Operating Income
-51517000
-7.2%
-48035000
-80.9%
-26553000
+30.2%
-38059000
-15.5%
-32965000
EBITDA
-51132000
-7.3%
-47644000
-82.5%
-26109000
+30.5%
-37560000
-15.9%
-32394000
Net Income
-47969000
-7.2%
-44727000
-84.8%
-24208000
+30.0%
-34568000
-14.9%
-30087000
EPS (Basic)
$-0.79
-3.9%
$-0.76
-68.9%
$-0.45
+29.7%
$-0.64
+3.0%
$-0.66
EPS (Diluted)
$-0.79
-3.9%
$-0.76
-68.9%
$-0.45
+29.7%
$-0.64
+3.0%
$-0.66
Shares (Diluted)
60.9M
+3.2%
59.0M
+9.5%
53.9M
+0.4%
53.7M
+17.3%
45.8M
Maze Therapeutics (MAZE) — Financials